SARS-CoV-2 immune evasion by variant B.1.427/B.1.429
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
SARS-CoV-2 entry is mediated by the spike (S) glycoprotein which contains the receptor-binding domain (RBD) and the N-terminal domain (NTD) as the two main targets of neutralizing antibodies (Abs). A novel variant of concern (VOC) named CAL.20C (B.1.427/B.1.429) was originally detected in California and is currently spreading throughout the US and 29 additional countries. It is unclear whether antibody responses to SARS-CoV-2 infection or to the prototypic Wuhan-1 isolate-based vaccines will be impacted by the three B.1.427/B.1.429 S mutations: S13I, W152C and L452R. Here, we assessed neutralizing Ab responses following natural infection or mRNA vaccination using pseudoviruses expressing the wildtype or the B.1.427/B.1.429 S protein. Plasma from vaccinated or convalescent individuals exhibited neutralizing titers, which were reduced 3-6 fold against the B.1.427/B.1.429 variant relative to wildtype pseudoviruses. The RBD L452R mutation reduced or abolished neutralizing activity of 14 out of 35 RBD-specific monoclonal antibodies (mAbs), including three clinical-stage mAbs. Furthermore, we observed a complete loss of B.1.427/B.1.429 neutralization for a panel of mAbs targeting the N-terminal domain due to a large structural rearrangement of the NTD antigenic supersite involving an S13I-mediated shift of the signal peptide cleavage site. These data warrant closer monitoring of signal peptide variants and their involvement in immune evasion and show that Abs directed to the NTD impose a selection pressure driving SARS-CoV-2 viral evolution through conventional and unconventional escape mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2021) · Science · doi:10.1126/science.abg3055 · Cited by 2,581
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2020) · doi:10.1101/2020.12.24.20248822 · Cited by 2,557
A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology
Rambaut, A., Holmes, E. C., O’Toole, Á., Hill, V., McCrone, J. T., Ruis, C., du Plessis, L., & Pybus, O. G. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0770-5 · Cited by 2,543
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Barnes, C. O., Jette, C. A., Abernathy, M. E., Dam, K.-M. A., Esswein, S. R., Gristick, H. B., Malyutin, A. G., Sharaf, N. G., Huey-Tubman, K. E., Lee, Y. E., et al. (2020) · Nature · doi:10.1038/s41586-020-2852-1 · Cited by 1,599
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
McCallum, M., Marco, A. D., Lempp, F., Tortorici, M. A., Pinto, D., Walls, A. C., Beltramello, M., Chen, A., Liu, Z., Zatta, F., et al. (2021) · doi:10.1101/2021.01.14.426475 · Cited by 901
Self-citationN-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
McCallum, M., De Marco, A., Lempp, F. A., Tortorici, M. A., Pinto, D., Walls, A. C., Beltramello, M., Chen, A., Liu, Z., Zatta, F., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.028 · Cited by 901
Self-citationSARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies
Collier, D. A., De Marco, A., Ferreira, I. A. T. M., Meng, B., Datir, R., Walls, A. C., Kemp S, S. A., Bassi, J., Pinto, D., Fregni, C. S., et al. (2021) · doi:10.1101/2021.01.19.21249840 · Cited by 729
Self-citationLiu, Z., VanBlargan, L. A., Bloyet, L.-M., Rothlauf, P. W., Chen, R. E., Stumpf, S., Zhao, H., Errico, J. M., Theel, E. S., Liebeskind, M. J., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.01.014 · Cited by 725
Deng, X., Garcia-Knight, M. A., Khalid, M. M., Servellita, V., Wang, C., Morris, M. K., Sotomayor-González, A., Glasner, D. R., Reyes, K. R., Gliwa, A. S., et al. (2021) · doi:10.1101/2021.03.07.21252647 · Cited by 651 · cited 10×
“Total number of SARS-CoV-2 (grey) and B.1.427/B.1.429 VOC (blue/orange) sequences deposited on a monthly basis worldwide (C), in the US (D) and in California (E).”
BackgroundInfluential
Research works printed but not linked: 49
- 10.1126/science.abb2507 · DOI · Paper page
- 10.1038/nature16988 · DOI · Paper page
- 10.1016/bs.aivir.2019.08.002 · DOI · Paper page
- 10.1038/s41586-020-2012-7 · DOI · Paper page
- 10.1016/j.cell.2020.02.052 · DOI · Paper page
- W. T. Soh , Y. Liu , E. E. Nakayama , C. Ono , S. Torii , H. Nakagami , Y. Matsuura , T. Shioda , H. Arase , bioRxiv, in press.
- 2021, AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells, Cell Res., 31, 126, 10.1038/s41422-020-00460-y · DOI · Paper page
- 2020, Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody, Nature, 583, 290, 10.1038/s41586-020-2349-y · DOI · Paper page
- 2020, Veesler, Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology, Cell, 183, 1024, 10.1016/j.cell.2020.09.037 · DOI · Paper page
- 10.1126/science.abd0827 · DOI · Paper page
- 10.1126/science.abd0831 · DOI · Paper page
- 10.1016/j.cell.2021.03.029 · DOI · Paper page
- 10.1126/science.abc6952 · DOI · Paper page
- 10.1038/s41586-021-03324-6 · DOI · Paper page
- 10.1038/s41586-020-2456-9 · DOI · Paper page
- 10.1101/2020.09.30.318972 · DOI
- 10.1101/2020.12.29.424482 · DOI
- 2021, A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies, Nat. Commun., 12, 1715, 10.1038/s41467-021-21968-w · DOI · Paper page
- G. Song , W.-T. He , S. Callaghan , F. Anzanello , D. Huang , J. Ricketts , J. L. Torres , N. Beutler , L. Peng , S. Vargas , J. Cassell , M. Parren , L. Yang , C. Ignacio , D. M. Smith , J. E. Voss , D. Nemazee , A. B. Ward , T. Rogers , D. R. Burton , R. Andrabi , bioRxiv, in press.
- 10.1038/s41586-021-03402-9 · DOI · Paper page
- 2021, Others, Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings, January, 12, 2021
- 10.1038/s41586-021-03412-7 · DOI · Paper page
- 10.1038/s41586-021-03398-2 · DOI · Paper page
- 10.1101/2021.02.22.432189 · DOI
- 10.1101/2021.03.06.434193 · DOI · Paper page
- 10.1101/2021.03.09.434607 · DOI · Paper page
- 10.1101/2021.02.10.430696 · DOI
- 2021, Correlates of protection against SARS-CoV-2 in rhesus macaques, Nature, 590, 630, 10.1038/s41586-020-03041-6 · DOI · Paper page
- 10.1038/s41591-021-01285-x · DOI · Paper page
- 10.1016/j.cell.2021.03.013 · DOI · Paper page
- 10.1016/j.chom.2021.03.009 · DOI · Paper page
- 2020, The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity, Cell, 182, 1284, 10.1016/j.cell.2020.07.012 · DOI · Paper page
- 10.1101/2021.02.17.431683 · DOI
- 2020, Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding, Cell, 182, 1295, 10.1016/j.cell.2020.08.012 · DOI · Paper page
- 10.1016/j.cell.2021.01.037 · DOI · Paper page
- 10.1016/j.cell.2020.10.049 · DOI · Paper page
- 10.1056/NEJMc2031364 · DOI · Paper page
- E. Andreano , G. Piccini , D. Licastro , L. Casalino , N. V. Johnson , I. Paciello , S. D. Monego , E. Pantano , N. Manganaro , A. Manenti , R. Manna , E. Casa , I. Hyseni , L. Benincasa , E. Montomoli , R. E. Amaro , J. S. McLellan , R. Rappuoli , bioRxiv, in press.
- 2020, Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants, Elife, 9, e61312, 10.7554/eLife.61312 · DOI · Paper page
- 10.1101/2021.02.14.431043 · DOI · Paper page
- 10.1186/1471-2105-6-31 · DOI · Paper page
- 10.1093/molbev/mst010 · DOI · Paper page
- 10.1126/science.1205669 · DOI · Paper page
- 10.1073/pnas.94.26.14764 · DOI · Paper page
- 10.1128/JVI.02055-15 · DOI · Paper page
- 10.3390/v12050513 · DOI · Paper page
- 10.1101/2021.03.15.435528 · DOI
- 2020, Human immunodeficiency virus-1 viral load is elevated in individuals with reverse-transcriptase mutation M184V/I during virological failure of first-line antiretroviral therapy and is associated with compensatory mutation L74I, J. Infect. Dis., 222, 1108, 10.1093/infdis/jiz631 · DOI · Paper page
- 10.1038/s41467-020-15562-9 · DOI · Paper page
Cited by
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
Mlcochova, P., Kemp, S. A., Dhar, M. S., Papa, G., Meng, B., Ferreira, I. A. T. M., Datir, R., Collier, D. A., Albecka, A., Singh, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03944-y · Cited by 1,337
Self-citationEarly treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab
Gupta, A., Gonzalez-Rojas, Y., Juarez, E., Crespo Casal, M., Moya, J., Falci, D. R., Sarkis, E., Solis, J., Zheng, H., Scott, N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107934 · Cited by 1,086
Fiolet, T., Kherabi, Y., MacDonald, C.-J., Ghosn, J., & Peiffer-Smadja, N. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.005 · Cited by 911
Proal, A. D., & VanElzakker, M. B. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.698169 · Cited by 876
SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway
Willett, B. J., Grove, J., MacLean, O. A., Wilkie, C., De Lorenzo, G., Furnon, W., Cantoni, D., Scott, S., Logan, N., Ashraf, S., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01143-7 · Cited by 785
Metadata
- Authors
- McCallum, M., Bassi, J., Marco, A. D., Chen, A., Walls, A. C., Iulio, J. D., Tortorici, M. A., Navarro, M.-J., Silacci-Fregni, C., Saliba, C., Agostini, M., Pinto, D., Culap, K., Bianchi, S., Jaconi, S., Cameroni, E., Bowen, J. E., Tilles, S. W., Pizzuto, M. S., Guastalla, S. B., Bona, G., Pellanda, A. F., Garzoni, C., Van Voorhis, W. C., Rosen, L. E., Snell, G., Telenti, A., Virgin, H. W., Piccoli, L., Corti, D., & Veesler, D.
- Venue
- bioRxiv (Cold Spring Harbor Laboratory)
- Publisher
- openRxiv
- Published
- 2021-04-01
- OpenAlex
- W3144086685
- Cited by
- 127
- References
- 20
- Type
- posted content
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SARS-CoV-2 immune evasion by variant B.1.427/B.1.429. https://app.cochat.ai/papers/10.1101/2021.03.31.437925
- The paper
- McCallum, M., Bassi, J., Marco, A. D., Chen, A., Walls, A. C., Iulio, J. D., Tortorici, M. A., Navarro, M.-J., Silacci-Fregni, C., Saliba, C., Agostini, M., Pinto, D., Culap, K., Bianchi, S., Jaconi, S., Cameroni, E., Bowen, J. E., Tilles, S. W., Pizzuto, M. S., . . . Veesler, D. (2021). SARS-CoV-2 immune evasion by variant B.1.427/B.1.429. bioRxiv (Cold Spring Harbor Laboratory). https://doi.org/10.1101/2021.03.31.437925
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.